{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinsonâ€™s disease (PD). The I2020T mutation alters kinase activity and is associated with PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the role of LRRK2 mutations in PD pathogenesis, linking altered kinase activity to disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase activity assays were used to assess ATP affinity and inhibitor sensitivity.",
          "judgment": "Yes",
          "reasoning": "The enzymatic assay directly models LRRK2's role in PD by measuring kinase activity, which is relevant to disease pathogenesis."
        },
        {
          "step_name": "Step 3a: Variant Controls",
          "extracted_paper_info": "The study compares I2020T activity against wild-type but does not explicitly mention other control variants.",
          "judgment": "No",
          "reasoning": "While wild-type is used as a control, there are no known benign or pathogenic variant controls mentioned."
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The assay is a standard method for assessing kinase activity and inhibitor sensitivity.",
          "judgment": "Yes",
          "reasoning": "The enzymatic assay is broadly accepted in the field, supporting its validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "I2020T shows increased ATP affinity and resistance to inhibitors, suggesting a pathogenic effect.",
          "judgment": "Moderate Support",
          "reasoning": "The functional data supports a moderate likelihood of pathogenicity due to the mutation's impact on kinase activity."
        }
      ],
      "functional_evidence_strength": "PS3_moderate"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The G2019S mutation is associated with increased kinase activity and linked to PD.",
          "judgment": "Yes",
          "reasoning": "The paper defines LRRK2 mutations, including G2019S, as causing PD through altered kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase activity assays were employed.",
          "judgment": "Yes",
          "reasoning": "The enzymatic assay directly assesses LRRK2 function, relevant to PD."
        },
        {
          "step_name": "Step 3a: Variant Controls",
          "extracted_paper_info": "Wild-type is used as a control, but no explicit mention of other variants.",
          "judgment": "No",
          "reasoning": "Lacks detailed controls beyond wild-type comparison."
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The assay is a standard method in the field.",
          "judgment": "Yes",
          "reasoning": "The enzymatic assay's acceptance validates its use."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "G2019S shows increased sensitivity to inhibitors, indicating a pathogenic effect.",
          "judgment": "Moderate Support",
          "reasoning": "The functional data supports moderate likelihood of pathogenicity due to its impact on kinase activity."
        }
      ],
      "functional_evidence_strength": "PS3_moderate"
    }
  ]
}